Introduction
Immune homeostasis depends on the regulated differentiation of naïve CD4
1 T cells into effector T-helper (Th) and induced regulatory (iTreg) T-cell lineages. 1 Effector Th cells protect against infections and tumors but may mediate autoimmune disease if their activation is unregulated 2, 3 or if they fail to die after activation. [4] [5] [6] iTreg cells are complementary to thymus-derived natural regulatory T (nTreg) cells 7 and dampen excessive inflammation. 8 The differentiation of Th cell lineages is initiated by activation of naïve CD4 1 T cells in the appropriate cytokine milieu and determined by the lineage-specific transcription factors T-bet (Th1), GATA3 (Th2), and ROR-gt (Th17) in effector T cells and Foxp3 in iTreg. Th1, Th2, and Th17 cells secrete distinct cytokinesrespectively, interferon-g (IFN-g), interleukin 4 (IL-4), and IL-17-which, in concert with lineage-specific transcription factors inhibit differentiation of the other T-cell lineages. 9 For example, counter-regulation occurs between Th1 and Th2 lineages through T-bet, GATA-3, and STAT4 10, 11 ; between Th1 and Th17 lineages through T-bet, Runx1, and ROR-gt 12 ; and between effector Th and iTreg cells through T-bet, GATA3, ROR-gt, Runx1, and Foxp3. [13] [14] [15] [16] Th1, Th2, Th17, and iTreg cells also produce the anti-inflammatory cytokine IL-10, which is a crucial feedback regulator of diverse immune responses. 17 Epigenetic regulation through DNA methylation, histone modification, and noncoding RNAs is essential to fine-tune gene expression and stabilize cell lineages 18 during naïve CD4 1 T-cell differentiation. 19, 20 The diversity of epigenetic modifications creates the potential for considerable redundancy at each gene locus. For histones, only a few core modifications seem to characterize genes as active or accessible, inactive but poised, or silent. 21 Dimethylation or trimethylation of histone 3 lysine 9 (H3K9) or H3K27, often found in the heterochromatin or at discrete sites within active genes, can repress inappropriate transcription. 20 Depletion of the methyltransferase SUV39H1 that mediates H3K9 trimethylation (H3K9me3) in Th2 cells results in transcription of the Th1 cytokine Ifng. 22 Effector T-cell signature cytokine loci such as the Ifng locus in Th2 cells 23, 24 and the Il4 locus in Th1 cells 25 are marked by repressive H3K27me3 marks. In Th2, Th17, and iTreg lineages, the Tbx21 locus encoding the Th1-cell transcription factor T-bet is "poised" for activation or repression by the combination of active H3K4me3 and repressive H3K27me3 marks. 26 It was suggested that the Th2 transcription factors GATA3 and STAT6 recruit the polycomb methyltransferase Ezh2 to the Ifng promoter and that H3K27me3 is associated with repression of IFN-g transcription in Th2 cells. 27 However, it was also reported that recruitment of Ezh2 was required for both IFN-g and IL-4 production in differentiated Th1 and Th2 cells. 28 The polycomb repressive complex (PRC) proteins form 2 closely related complexes-PRC2 and PRC1. H3K27 trimethylation is catalyzed by the methyltransferases Ezh2 or Ezh1, 29 which are core components of PRC2 along with Suz12 and Eed.
30 PRC1 occupies some of the PRC2 sites 31 and may function downstream of PRC2. 32 Effector CD4 1 T cells lacking the PRC1 proteins Bmil 33 and Ring1B 34 have impaired survival, at least in part because of activation of apoptosis mediated by Noxa and Bim. EZH2 overexpression and activating mutations are implicated in tumorigenesis and correlate with poor prognosis in several tumor types. 35 This spurred the development of EZH2 inhibitors that, by inducing tumor cell growth arrest and cell death, show therapeutic promise in cancer. 36 Previously, it was reported that cytosolic Ezh2 was required for actin polymerization after T-cell receptor (TCR) ligation. 37 A role for Ezh2 in suppressing Th1 and Th2 cytokine production 38 and cell death 39 has recently been reported. It is not entirely clear whether Ezh2-PRC2 plays a role in H3K27me3 at cytokine loci in naïve CD4
1 T cells and whether H3K27me3 has a nonredundant role in Th cell lineage differentiation and survival. Here, by analyzing the effects of T cell-specific Ezh2 deletion, we show that Ezh2-PRC2 plays a distinct, nonredundant role in regulating the fate of differentiating naïve CD4 1 T cells. .CD4Cre mice were established by crossing Ezh2 f1/f140 with CD4Cre transgenic mice. 41 The effects of Ezh2 deletion on T-cell development and on the proportion and phenotype of peripheral naïve and memory CD4
Materials and methods
1 T cells are shown in supplemental Figure 1 .
We examined the differentiation of Th1, Th2, Th17, and iTreg lineages in vitro 42 ( Figure 1A ) after sorting naïve CD4 Figure 1B ) and comprised similar proportions of live cells (supplemental Figure 2A) . However, by day 6, the proportion of Ezh2 fl/fl .CD4Cre effector (Th0, Th1, Th2, Th17) cells, but not iTreg cells, had decreased (supplemental Figure 2B ), suggesting increased cell death in these effector lineages. We then characterized Th0, Th1, Th2, and Th17 differentiation at day 4 and iTreg differentiation at days 4 to 6. Under nonpolarizing Th0 conditions, the proportions of cells expressing the Th1 cytokine IFN-g and the Th2 cytokines IL-4, IL-5, and IL-13 were increased in Ezh2 fl/fl .CD4Cre cells. IL-10, a feedback regulator of Th1 and Th2 responses, was also dramatically increased in Th0 cells ( Figure 1C ). The production of IL-4, IL-5, and IL-13 was increased in Th2 cells, which also had the most prominent upregulation of IL-10 ( Figure 1D ). Based on IL-17A expression, Th17 cell differentiation was similar between control and Ezh2 fl/fl
.CD4Cre naïve CD4 1 T cells ( Figure 1E ). Under both Th1 and iTreg conditions, IFN-g overproduction was observed ( Figure 1F ). The presence of IFN-g-blocking antibody, normally required to permit differentiation of Th2 and Th17 cells ( Figure 1A ), could have masked an effect of Ezh2 deficiency on Th2 (as shown in Figure 1D ) and Th17 differentiation. We then examined differentiation in the absence of IFN-g-blocking antibody. Under Th2 conditions, a substantial proportion of Ezh2 fl/fl .CD4Cre cells expressed IFN-g and had reduced expression of Gata-3 and IL-4, although their expression of IL-10 was sustained ( Figure 2D ). Under Th17 conditions, differentiation was unchanged ( Figure 2D , right panel), possibly because of the antagonistic effects of IL-6 44 and/or transforming growth factor (TGF)-b 45 to suppress Th1 differentiation. Overall, these results show that Ezh2 suppresses IFN-g expression, permitting Th2 and iTreg differentiation.
In mixed cultures, Foxp3 expression in WT cells exposed to IFN-g from Ezh2 fl/fl .CD4Cre cells remained largely uncompromised. This suggested that the absence of Ezh2 was associated with intrinsic .CD4Cre naïve CD4
1 T cells did not produce IFN-g when activated by PMA and ionomycin over a short 5-hour period insufficient for the expression of newly transcribed cytokine genes ( Figure 2E ). This suggested a requirement for prolonged T-cell activation for increased expression of genes, leading to skewed Th1 differentiation. Under differentiation conditions at day 4, Ezh2 fl/fl .CD4Cre cells had higher STAT1 and STAT4 phosphorylation when they were re-stimulated by PMA and ionomycin for 5 hours in the absence of IFN-g-blocking antibody ( Figure 2F ), demonstrating that excessive IFN-g production promoted activation of genes for Th1 differentiation.
Suppression of IFN-g production by Ezh2 requires other PRC2 components
To gain insight into how Ezh2 regulates IFN-g production, we examined expression of the PRC2 components during T-cell differentiation. Ezh2 transcription was dramatically increased upon T-cell activation and differentiation, but in the absence of Ezh2, transcription of Ezh1 and Suz12 was unchanged ( Figure 3A) . In naïve CD4 1 T cells, expression of Ezh1 and Suz12 protein, and global H3K27me3, was comparable in Ezh2 fl/fl .CD4Cre and control cells ( Figure 3B ). In WT cells, activation and differentiation increased the expression of PRC2 components and decreased global H3K27 trimethylation (supplemental Figure 3) . In iTreg cells, loss of Ezh2 resulted in a further marked global reduction of the repressive H3K27me3 marks ( Figure 3C ). Ezh2
.CD4Cre cells had similar Ezh2 expression compared with WT or Ezh2 fl/fl controls (see Figure 3B ), and we did not observe significant differences in iTreg cell differentiation in these cells (data not shown). Taken together, these findings indicate that Ezh2 is not required for the expression or maintenance of PRC2 components and is not essential to maintain global H3K27 trimethylation in naïve CD4 1 T cells. However, after proliferation and differentiation, Ezh2 has a clear role in global H3K27me3. Ezh2 was previously reported to have a PRC2-independent role under certain experimental conditions. 46 To determine whether Ezh2 functions within the context of PRC2, we depleted the nonredundant PRC2 component Suz12 by retroviral-mediated shRNA knockdown. In naïve CD4
1 T cells, this resulted in a global reduction of H3K27me3 ( Figure 3D ), which was in contrast to Ezh2 depletion ( Figure 3B ). Similarly to Ezh2 fl/fl .CD4Cre cells, Suz12-depleted naïve CD4 1 T cells also exhibited increased IFN-g and decreased
Foxp3 expression under iTreg differentiation conditions ( Figure 3E ).
In Th0 cells, expression of all lineage-specific cytokines was significantly increased in Suz12-kd compared with nonsilencing (Nons) controls ( Figure 3F ). Of note, we also observed a decrease in the expression of Ezh2 in naïve CD4 1 T cells depleted of Suz12
( Figure 3D ). These results further confirm that PRC2 suppresses Th1 and Th2 cytokine gene expression in nonpolarized conditions, most likely dependent on Ezh2 in the context of PRC2.
Association of genes regulated by Ezh2 with trimethylation of histone 3 lysine 27
We performed RNA-seq to identify genes regulated by Ezh2 during T-cell activation and differentiation. Loss of Ezh2 altered the expression of 1328 genes in Th0 (supplemental Figure 4A and supplemental Table 1 ) and 1979 genes in iTreg cells (supplemental Figure 4B and supplemental Table 2 ). Gene expression changes were positively correlated in both cell types ( Figure 4A ), indicating that Ezh2 targets similar genes in these cells. As expected, Ifng was one of the genes most increased in expression after loss of Ezh2. In addition, expression of Tbx21 homolog Eomes, a transcription factor that regulates IFN-g production, 38 was also significantly increased. To identify gene networks regulated by Ezh2, we performed competitive gene set testing using curated gene sets from the Broad Institute Molecular Signatures Database. Gene sets associated with PRC2, interferon responsive genes, and apoptosis were significantly more prominent in Ezh2 fl/fl .CD4Cre Th0 cells, whereas targets of 
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For personal use only. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From To determine to what extent Ezh2 uses H3K27 trimethylation to regulate gene expression during T-cell differentiation, we compared our data with publicly available H3K27me3 ChIP-seq data from naïve CD4 1 T and iTreg cells. 26 This revealed that genes upregulated in . Furthermore, 404 of these genes also showed a concomitant increase in expression in Ezh2 fl/fl .CD4Cre Th0 cells (supplemental Table 5 ), suggesting that these loci are likely direct Ezh2-PRC2 targets.
We also examined whether Ezh2 is required for H3K27me3 at the Th1 and Th2 loci before and after naïve CD4 Figure 4C ). In the absence of Ezh2, significant loss of H3K27me3 was observed in the Gata3 and Il10 promoters in naïve, in the Il4 promoter in Th1, and in the Il10 promoter in Th2 cells. H3K4me3 marks were also enriched at the Th2 loci, except at the Il4 promoter in Th1 cells ( Figure 4D ). These results suggest that Th1 and Th2 loci in naïve CD4 1 T cells are marked with repressive and active histone marks, and that Ezh2 has a nonredundant role in H3K27me3 at specific loci before naïve cell differentiation.
Ezh2 differentially controls cell survival of effector Th and iTreg cells
The number of Ezh2 fl/fl .CD4Cre effector Th but not iTreg cells decreased dramatically compared with control cells by 6 days after differentiation (supplemental Figure 1B) , suggesting that cell death pathways were differentially activated in Ezh2 fl/fl .CD4Cre
Th cells. MLKL is a pseudokinase required to induce necroptosis. 47, 48 Intriguingly, we observed an increase in transcription ( Figure 4A ), loss of H3K27me3 ( Figure 4B ), and expression ( Figure 5B ) of MLKL in both Ezh2 fl/fl .CD4Cre Th0 and iTreg cells. Furthermore IFN-g has been implicated in RIPK1/RIPK3-mediated necroptotic cell death in Fadd 2/2 cells. 49 We therefore tested whether Ezh2 fl/fl .CD4Cre
Th0 cells died by necroptosis, by treating Ezh2 fl/fl .CD4Cre naïve Th0 cell death at day 5, and IFN-g or FasL blockade provided a small but significant survival advantage ( Figure 5E ). The effects of blocking antibodies persisted into day 6, but cell death was not completely prevented ( Figure 5E ). Thus, in parallel with T helpercell differentiation skewing, multiple death pathways appeared to be activated in Ezh2-null effector CD4 1 T cells ( Figure 5F ).
Ezh2 controls differentiation and survival of effector Th cells in vivo
We then investigated the effect of Ezh2 on T-cell differentiation and survival in vivo. Mixed bone marrow chimeric mice containing WT (Ly5. IFN-g plays a critical role in the pathogenesis of many autoimmune diseases, 51 and relative deficiency of IFN-g characterizes some chronic infections and tumor tolerance in humans. 52 To examine the function of EZH2 in human CD4
1 T cells, we used GSK-126, a highly selective inhibitor of EZH2 methyltransferase. 53 GSK-126 significantly increased IFN-g production in activated naïve CD4 1 T cells (Th0) and decreased the expression of FOXP3 in iTreg cells ( Figure 7A-C) . By day 6, we observed significantly reduced numbers of both Th0 and iTreg cells after treatment with GSK-126 ( Figure 7D ). These effects were accompanied by a decrease in EZH2 and in global H3K27me3 expression in some but not all BLOOD, 31 JULY 2014 x VOLUME 124, NUMBER 5
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Discussion
H3K27me3 by PRC2 in differentiated Th cells is associated with gene repression and reflects the cellular context. Thus, H3K27me3 is enriched at T-cell signature cytokine loci, which specify opposing T-cell lineages (eg, at the Ifng locus in Th2 cells 23, 24 and Il4 locus in Th1 cells). 25 In naïve CD4 1 T cells, we found that the lack of PRC2, after depletion of its nonredundant subunit Suz12, diminished global H3K27me3. Ezh2 was required for global H3K27me3 in differentiated Th cells but not in naïve CD4 1 T cells, a function potentially compensated for by Ezh1. 29 We found that H3K27me3 at particular loci, including Ifng, Gata3, and Il10, is specifically dependent on PRC2-Ezh2 in naïve CD4 further permitting the access of transcription factors including T-bet and Eomes required for IFN-g transcription in differentiated Th lineages. 38 We did not observe IFN-g overproduction in Ezh2-null cells under Th17 differentiation conditions, with or without IFN-g blockade, which suggests that exposure to IL-6 44 However, when Th2 cells were differentiated in the absence of IFNg blocking antibody, the production of Th2 cytokines was reduced in Ezh2-null cells, likely because of the antagonistic effects of T-bet and STAT4 on GATA-3 expression. 10, 11 The production of the antiinflammatory cytokine IL-10 in Ezh2 fl/fl .CD4Cre Th0 and Th2 cells could result from the loss of H3K27me3 at the Il10 locus in naïve CD4 1 T and Th2 cells and the expression of the transcription factor Gata-3 55 in these cell types. A recent study by Tumes et al 38 demonstrated an enhanced asthmalike pathology when recipient mice were transferred with Ezh2-null Th2 cells differentiated in vitro and that aged Ezh2-null mice had enriched effector memory Th2 cells. It was unclear whether these Th2 cells underwent cell death and produced IL-10 and IFN-g transferred in vivo physiological impact of Ezh2 deficiency may depend on the models studied. We demonstrated that Ezh2 maintains the survival of effector Th0 cells by suppression of extrinsic and intrinsic death receptor pathways. This is consistent with a recent study 39 
in which donor
Ezh2-null effector T cells initially expanded but then underwent apoptotic death (as we observed in vitro and in vivo) and failed to elicit graft-versus-host disease in recipient mice. Cell death associated with loss of PRC2-Ezh2 may not be a result of direct loss of H3K27me3 at death gene loci and or rescued by single-gene deletion. For example, depletion of Bim was insufficient to rescue Ezh2-mediated cell death. 39 Cell death is unlikely to be a consequence of excessive IFN-g production because (1) significant cell death was observed in Th2 and Th17 cells under differentiation conditions that did not result in IFN-g production; and (2) Q-VDOph rescued Ezh2 fl/fl .CD4Cre Th0 cell death without altering IFN-g production. Future experiments are required to identify potential transcription factors that enhance the expression of death receptors and/or their ligands. The role of PRC2-Ezh2 in governing differentiation and survival of T cells has therapeutic implications. EZH2 inhibitors induce cancer cell growth arrest and cell death 36 but may also promote IFN-g-dependent antitumor immunity if a means could be found to prolong cell survival. Conversely, agents that promote EZH2 function may suppress Th1-dependent autoimmune disease.
